[CAS NO. 23623-31-6] Lankacidin C
PRODUCTS SPECIFICATIONS [23623-31-6]
DESCRIPTION [23623-31-6]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 459.53 |
| Molecular Formula | C25H33NO7 |
| SMILES | C[C@@H]1[C@H]2C[C@H](O)/C=C/C(C)=C/C[C@H](O)/C=C/C(C)=C/[C@@H](NC(C(C)=O)=O)[C@@](C(O2)=O)(C)C1=O |
Summary
In Vivo
Lankacidin C (75-1000 mg/kg; i.p.; once daily for 5 days) prolongs the mean survival time of (C57BL/6×DBA/2) F1 (BDF1) mice with dose-dependent manner. Lankacidin C (1000 mg/kg) significantly inhibits the growth of B-16 melanoma in C57BL/6 mice implanted B-16 melanoma
[2]
.
Lankacidin C (300 mg/kg; i.p.; once daily for 6 days) inhibits the activity of L-1210 cells that resistance to 6-Mercaptopurine (HY-13677) or Cytosine Arabinoside (HY-13605) in BDF1 mice bearing L-1210/6-Mercaptopurine or L-1210/Cytosine Arabinoside
[2]
.
Lankacidin C (10-100 mg/kg; i.p.; once daily for 5 days) significantly prolongs the mean survival time of C3H/He mice bearing 6C3HED/OG or 6C3HED/RG lymphosarcoma
[2]
.
Lankacidin C (500 mg/kg; i.p.; once daily for 3 or 4 days) suppresses the production of antibody against sheep erythrocytes in ICR mice when administered before or after antigenic stimulation
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | C57BL/6, C3H/He, ICR and (C57BL/6×DBA/2) F1 (BDF1) mice [2] . |
| Dosage: | 10, 20, 25, 30, 40, 50, 100, 150, 250, 300, 500, 600 or 1000 mg/kg |
| Administration: | Intraperitoneal injection; once daily for 3, 4, 5 or 6 days |
| Result: | Inhibited the growth of L1210 leukemia, B16 melanoma and 6C3 HED/OG or 6C3 HED/RG lymphosarcoma cells. |
Source
Streptomyces spp.
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
References